Skip to main content
BLGO
OTC Industrial Applications And Services

BioLargo Q2 2026: Revenue Plunges 61%, Going Concern Warning Reiterated

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Industrial
Sentiment info
Negative
Importance info
8
Price
$0.104
Mkt Cap
$33.372M
52W Low
$0.095
52W High
$0.234
52W Position info
9.5% above low
Off High info
55% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

BLGO is trading near its 52-week low of $0.095 (9.5% above the low) on light trading volume (0.3× avg).

Summary

BioLargo's Q2 2026 10-Q reveals a 61% revenue drop, $7.4M net loss, and a going concern warning, with continued reliance on dilutive financing.


Key Events · Earnings and Guidance · BLGO

  • Revenue Collapse

    Total revenue fell 61% to $2.36M for H1 2026, primarily due to the loss of the Pooph pet odor control customer, which had accounted for 69% of revenue in H1 2025.

  • Going Concern Warning

    Management reiterates substantial doubt about the company's ability to continue as a going concern, citing insufficient gross profits to fund operations and a working capital deficit of $1.3M.

  • Cash Burn Accelerates

    Net cash used in operating activities was $6.0M for H1 2026, up from $3.9M in H1 2025, leaving only $2.2M in cash and equivalents as of June 30, 2026.

  • Dilutive Financing Continues

    BioLargo entered a $10M equity line with Clearthink, selling 3.25M shares for $391K in Q2 and an additional 3.5M shares for $376K after quarter end, further diluting shareholders.


Analysis · BLGO · Industrial Applications And Services

BioLargo's Q2 2026 results show a 61% revenue decline to $2.36M for the first half, driven by the loss of its largest customer, Pooph. The company posted a net loss of $7.4M and used $6.0M in operating cash, leaving only $2.2M in cash against a working capital deficit of $1.3M. Management again states substantial doubt about its ability to continue as a going concern. The company is relying on dilutive financing, including a new $10M equity line with Clearthink, of which $391K was drawn in Q2 and another $376K after quarter end. Clyra Medical, its 48%-owned subsidiary, raised $3.4M in debt guaranteed by BioLargo, adding contingent liability. The material weakness in internal controls persists. This filing confirms the company's deteriorating financial position and survival risk.

At the time of this filing, BLGO was trading at $0.10 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $33.4M. The 52-week trading range was $0.10 to $0.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BLGO - Latest Insights

BLGO
May 15, 2026, 4:38 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.13263
Real-time Price: $0.104 info
Change: -$0.02863 (-22%) info
Market Cap: $33.372M info
BLGO
May 15, 2026, 4:29 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.13263
Real-time Price: $0.104 info
Change: -$0.02863 (-22%) info
Market Cap: $33.372M info
BLGO
May 06, 2026, 6:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.15564
Real-time Price: $0.104 info
Change: -$0.05164 (-33%) info
Market Cap: $33.372M info
BLGO
May 05, 2026, 3:00 AM EDT
Source: Access Newswire
Importance Score:
8
Price at Filing: $0.156875
Real-time Price: $0.104 info
Change: -$0.052875 (-34%) info
Market Cap: $33.372M info
BLGO
May 04, 2026, 5:00 AM EDT
Source: Access Newswire
Importance Score:
8
Price at Filing: $0.1527
Real-time Price: $0.104 info
Change: -$0.0487 (-32%) info
Market Cap: $33.372M info